Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2009-11-02 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that it has received approval from AFSSaPS to start an extension of the Phase I clinical trial with its monoclonal antibody IPH 2101 in pat
Regulatory Filings Classification · 95% confidence The document is a press release dated November 2, 2009, announcing that Innate Pharma received approval from AFSSaPS to extend a Phase I clinical trial for its drug candidate IPH 2101 in Acute Myeloid Leukemia (AML) patients. It details the trial extension, preliminary safety/pharmacodynamic results, future plans (Phase II/registration trials), and provides background on the drug, the disease, and NK cells. This content structure—a formal announcement of clinical trial progress, regulatory milestones, and future development plans, issued via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on specific clinical/regulatory updates rather than comprehensive financial results (like a 10-K or IR) or management changes (MANG), and it is a direct announcement of news rather than a report itself, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the nature of clinical trial updates being frequently released outside of standard quarterly earnings cycles, and the document being a direct news announcement, RNS is a strong candidate. However, many companies use ER for significant clinical/pipeline updates even if not strictly quarterly earnings. Since it is a direct announcement of a significant operational/regulatory event (trial extension approval), and not a summary of financial performance, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback for specific operational news that isn't a core financial report or a specific proxy/insider filing. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR).
2009-11-02 English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports Phase II clinical data with IPH 1101 in oncology
Earnings Release Classification · 98% confidence The document is a press release dated September 21, 2009, reporting interim clinical trial data for a drug candidate (IPH 1101) in oncology, specifically mentioning response rates (ORR, CRR) and adverse events. It also announces a conference call to discuss these results. This content structure—reporting key financial/operational results (clinical data milestones) immediately followed by an invitation to an earnings/results call—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript of the call itself (CT). Since it is the initial announcement of period results (clinical trial data update), ER is the most appropriate classification. H1 2009
2009-09-21 English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) présente des resultats cliniques de Phase II avec IPH 1101 en oncologie
Regulatory Filings Classification · 95% confidence The document is a press release dated September 21, 2009, announcing intermediate clinical trial results for a drug candidate (IPH 1101) in oncology, specifically mentioning data presented at the ESMO congress. It details efficacy rates, patient cohorts, and future plans regarding partnership seeking after final data release. The text explicitly mentions a conference call to present these results and directs investors to a presentation support on the company website. This structure—announcing key results and providing details about an upcoming call/presentation—is characteristic of an Earnings Release (ER) or a general announcement of results. Since it focuses on the release of specific, periodic financial/clinical performance data (even if clinical), and includes management commentary and a call invitation, 'ER' (Earnings Release) is the most appropriate fit among the options, as it covers the initial announcement of periodical results/performance highlights. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or merely an announcement of a report publication (RPA), as it contains the substantive results themselves.
2009-09-21 French
L’Assemblée Générale d’Innate Pharma (Euronext Paris: FR0010331421 – IPH) a autorisé le Directoire à acheter des actions de la Société dans le cadre de la mise en œuvre d’un programme de rachat d’acti
AGM Information Classification · 99% confidence The document is titled "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS VOTE PAR LES ACTIONNAIRES LORS DE L'ASSEMBLEE GENERALE MIXTE DU 23 JUIN 2009" and dated September 18, 2009. It details the objectives, maximum size, price, and duration of a share repurchase program authorized by shareholders at the AGM. This content directly relates to the company buying back or selling its own shares, which aligns perfectly with the definition for 'Transaction in Own Shares' (POS). Although it references an AGM authorization, the core subject is the execution plan for the share repurchase, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2009-09-18 French
The General Meeting of Innate Pharma (Euronext Paris: FR0010331421 – IPH) has authorized the Executive Board to purchase its own shares through a share repurchase program.
Transaction in Own Shares Classification · 99% confidence The document explicitly details the authorization and parameters for the company's program to purchase its own shares, referencing a resolution passed during the General Shareholders' Meeting on June 23, 2009. The content focuses entirely on the objectives, maximum number of shares, price, and duration of a share repurchase plan. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2009-09-18 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui qu’à partir du 21 septembre 2009 la Société a confié à Natixis Securities la mise en œuvre d’un contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is a press release dated September 18, 2009, announcing the implementation of a liquidity contract (contrat de liquidité) with Natixis Securities, involving the allocation of €300,000. This action relates to the company's capital structure and financing arrangements, specifically concerning market liquidity management. This fits best under 'Capital/Financing Update' (CAP), as it details a specific financial arrangement intended to support the stock price/liquidity, which is a form of capital management activity. It is not a standard regulatory report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2009-09-18 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.